36 results on '"Kamal Chamoun"'
Search Results
2. Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
3. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study
4. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
5. A case of neurocognitive deficit strongly related to dasatinib therapy
6. Early detection of transformation to BPDCN in a patient with MDS
7. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study
8. A case of neurocognitive deficit strongly related to dasatinib therapy
9. Nonbacterial Thrombotic Endocarditis
10. Achieving sustainable, environmentally viable, solarized vaccine cold chain system and vaccination program--an effort to move towards clean and green energy-driven primary healthcare in Lebanon.
11. An Experimental Evidence for Antibacterial Activity of Propolis on Bacteria from Lebanese Patients.
12. Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents.
13. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
14. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
15. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study.
16. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
17. Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia.
18. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
19. New Myelofibrosis Research from University of Utah Discussed (A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis).
20. Impact of Regional Income and Insurance Status on Survival of Multiple Myeloma Patients: Autologous Stem Cell Transplant as an Equalizer.
21. Socioeconomic Factors and Survival of Multiple Myeloma Patients.
22. Socioeconomic Factors Predict Long-Term Survival in Multiple Myeloma.
23. Ibrutinib monotherapy in relapsed/refractory CNS lymphoma: A retrospective case series.
24. Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience.
25. Early detection of transformation to BPDCN in a patient with MDS.
26. American Diplomacy Toward Lebanon : Lessons in Foreign Policy and the Middle East
27. Abstracts of the 53 Annual Conference of the Italian Society of Neurology
28. Reports from Weill Cornell Medicine Add New Data to Research in Myelodysplastic Syndromes (Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents)
29. New Myelofibrosis Research from University of Utah Discussed (A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis)
30. Who's Who in Lebanon 2007-2008
31. New B-Cell Lymphoma Study Results Reported from Stony Brook University Hospital [Effect of Prior Therapy and Disease Refractoriness On the Efficacy and Safety of Oral Selinexor In Patients With Diffuse Large B-cell Lymphoma (Dlbcl): a Post-hoc ...]
32. Amsterdam University Medical Center Researchers Yield New Study Findings on B-Cell Lymphoma (The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study)
33. New Findings from Institute Jules Bordet in the Area of B-Cell Lymphoma Described (Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study)
34. University Hospitals Seidman Cancer Center Researchers Release New Data on Multiple Myeloma (Socioeconomic Factors and Survival of Multiple Myeloma Patients)
35. Private Insurance, Higher Regional Incomes, and Certain Practice Settings Predict Longer Survival for People With Multiple Myeloma
36. PRIVATE INSURANCE, HIGHER REGIONAL INCOMES, AND CERTAIN PRACTICE SETTINGS PREDICT LONGER SURVIVAL FOR PEOPLE WITH MULTIPLE MYELOMA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.